340B disproportionate share (DSH) hospitals’ contract pharmacies and child sites often are in richer and less diverse places where more residents have health insurance compared with the hospitals’ own locations, according to a new study.
Healthcare consulting firm Avalere Health issued the analysis on April 18. One of the study’s authors said yesterday that Avalere performed it on its own behalf, not for a client. Avalere has done prior analyses of the 340B program financed by the drug industy-funded group Alliance for Integrity and Reform of 340B (AIR 340B) and the Federation of American Hospitals, the trade group of for-profit hospitals. For-profit hospitals are not eligible for the 340B program.
Many National Cancer Institute (NCI) designated cancer centers—most of which are affiliated with 340B hospitals—mark up the price of infused cancer therapies for patients with private insurance “substantially,” according to new research in JAMA Internal Medicine.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
